Every 10-Q that CME Group (CME) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CME filings page.
CME Group Inc. reported Q2 2026 total revenues of $1,706.2 million, slightly above Q2 2025. Net income was $1,041.8 million with diluted EPS of $2.88, compared with $1,025.1 million and $2.81 a year earlier.
For the six months ended June 30, 2026, revenues reached $3,586.3 million and net income $2,196.1 million, with diluted EPS of $6.06. Clearing and transaction fees dipped in Q2 but rose year to date, while market data and information services grew strongly. Total assets were $194,676.6 million, long-term debt $3,424.2 million, and operating cash flow $2,207.0 million. The company returned capital through $3,171.8 million of common dividends and repurchased 4,384,776 Class A shares for $1.2 billion, leaving $1.5 billion under its existing buyback program.
CME Group Inc. reported strong first-quarter 2026 results with higher trading activity and earnings. Total revenues rose to $1,880.1 million, up 14% from $1,642.3 million a year earlier, driven mainly by clearing and transaction fees of $1,542.6 million, up 15%.
Operating expenses increased 7% to $570.4 million, but operating income still climbed to $1,309.7 million from $1,108.0 million, lifting the operating margin to 69.7%. Net income grew to $1,154.3 million, up 21%, and diluted earnings per share improved to $3.18 from $2.62.
Higher investment income from performance bond and guaranty fund balances contributed to non‑operating income of $201.2 million. CME continued returning capital, paying common dividends of about $2,702.9 million and repurchasing 1.84 million Class A shares for roughly $538.7 million under its $3.0 billion buyback authorization.
CME Group Inc. reported Q3 2025 results with total revenue of $1,537.6 million versus $1,584.4 million a year ago as lower futures and options activity reduced clearing and transaction fees. Operating income was $972.6 million with a 63.3% operating margin. Net income was $908.0 million, and diluted EPS was $2.49.
Market data and information services grew to $202.5 million (up 14% year over year), partly offsetting softer trading revenues. Non‑operating income of $204.4 million reflected high investment income driven by reinvestment of performance bond collateral, net of distributions to clearing members.
Year‑to‑date, operating cash flow reached $3,143.2 million. The company paid dividends of $1.25 per share in Q3 (total $3.75 per share YTD) and repurchased 32,265 shares for $8.2 million. CME refinanced debt—retiring $750.0 million due 2025 and adding $750.0 million due 2030—bringing long‑term debt to $3,421.3 million. Subsequent event: on October 10, 2025, CME and S&P Global completed the sale of OSTTRA (EV $3.1 billion split 50/50); CME expects to recognize a ~$300.0 million gain in Q4 2025.